WASHINGTON (AP) — Drugmaker Pfizer has agreed to lower drug costs and invest $70 billion in U.S. manufacturing under a deal struck with the Trump administration, President Donald Trump said Tuesday.
The announcement, which Trump made with Pfizer CEO Albert Bourla at the White House, came as the Republican president has for months sought to lower drug costs. It also came as Washington was facing a federal government shutdown at midnight amid a standoff between Democrats and Republicans over health care and its costs.
Under the agreement, New York-based Pfizer will charge most-favored-nation pricing to Medicaid and guarantee that pricing on newly launched drugs, Trump said. That involves matching the lowest price offered in other developed nations.
“I can’t tell you how big this is,” the president said.
“I think today we are turning the tide and we are reversing an unfair situation,” Bourla said.
The president has been talking for months about the need to lower drug prices. In May, he issued an executive order that gave drugmakers 30 days to electively lower prices or face new limits on what the government will pay.
To persuade them to strike deals, Trump said he threatened to impose tariffs — a favorite tool of his to use as leverage across all areas of government — but that move could raise drug prices.
It’s unclear how the new policy will affect Medicaid patients who often pay a nominal co-payment of a few dollars to fill their prescriptions, but lower prices could help state budgets that fund the programs. Medicaid is the state and federally funded program for people with low incomes.
“This is something that most people said was not doable,” Trump said Tuesday.
One thing that is not doable, however, was Trump’s repeated claims that it would cut drug prices by more than 100%, “14, 15, 1600% reductions in some cases,” he said.
A 100% reduction would make the drugs free. Cuts greater than that would essentially mean people are paid to take the drugs.
Trump said he’s making deals with other drugmakers, and “they’re all coming in over the next week.”
Besides committing to lowering costs, Trump said, Pfizer agreed to spend $70 billion in domestic manufacturing facilities, becoming the latest in a string of major drugmakers to announce plans to build production in the United States.
The White House did not immediately release details about the investment, but Trump for months has spoken of a need to boost U.S. drug manufacturing.
Pfizer Inc. is one of the largest U.S. drugmakers. It produces the COVID-19 vaccine Comirnaty and the treatment Paxlovid. Its products also include several cancer drugs, the blood thinner Eliquis and the pneumonia vaccine Prevnar.
Trump sent letters in late July to executives at 17 pharmaceutical companies about changes he would like to see. Copies of the letters posted on social media note that U.S. prices for brand-name drugs can be up to three times higher than averages elsewhere.
The letters called for drugmakers to commit by Monday to offering what Pfizer agreed to: most-favored-nation pricing to Medicaid and new medications.
Trump also asked drugmakers to offer the lower pricing levels for drugs sold directly to consumers and businesses.
Trump has claimed that the U.S., with its higher drug prices, subsidizes care in other countries.
Drug prices for patients in the U.S. can depend on a number of factors, including the competition a treatment faces and insurance coverage. Most people have coverage through work, the individual insurance market or government programs like Medicaid and Medicare that shields them from much of the cost.
Drugmakers in the past couple of years have started launching websites to connect customers directly with some products like Lilly’s obesity treatment Zepbound or the blood thinner Eliquis from Pfizer and Bristol-Myers Squibb. That comes as patients have grown more comfortable with receiving care virtually after the practice exploded in popularity during the coronavirus pandemic.
___
Murphy reported from Indianapolis.
